Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors-Reference-Cited by-同舟云学术

Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors

Published:2023-01 Issue: Volume:179 Page:124-135
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Riedel Richard^ORCID,Fassunke Jana,Tumbrink Hannah L.,Scheel Andreas H.,Heydt Carina,Hieggelke Lena,Scheffler Matthias,Heimsoeth Alena,Nogova Lucia,Michels Sebastian^ORCID,Weber Jan-Phillip,Fischer Rieke N.,Eisert Anna,Westphal Theresa,Schaufler Diana,Siemanowski Janna,Ihle Michaela A.,Wagener-Ryczek Svenja,Castiglione Roberta^ORCID,Pappesch Roberto,Rehker Jan,Jürgens Jessica,Stoelben Erich,Bunck Anne,Kobe Carsten,Merkelbach-Bruse Sabine,Sos Martin L.,Büttner Reinhard,Wolf Jürgen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Targeting MET in lung cancer: will expectations finally be MET?;Drilon;J Thorac Oncol,2017

2. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Discov,2015

3. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers;Onozato;J Thorac Oncol,2009

4. MET-dependent solid tumours - molecular diagnosis and targeted therapy;Guo;Nat Rev Clin Oncol,2020

5. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients;Zehir;Nat Med,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion;Frontiers in Oncology;2024-04-16

3. MET alterations in advanced non-small cell lung cancer;Current Problems in Cancer;2024-04

4. KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression;Pathology - Research and Practice;2024-02

5. MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition;Journal of Thoracic Oncology;2024-01